Tahoora Mousavi

1 Introduction COVID–19 remains a global health problem and a challenge to the global public health system [1]. Following the recent widespread circulation of the omicron variant of SARS-CoV-2, there is a pressing need to develop new treatment strategies to reduce mortality and disability in patients [1-3]. SARS-CoV-2 is a member of the Orthocoronavirinae subfamily of the Coronaviridae family.

A prophylactic immunization against the disease COVID-19, caused by the SARS-CoV-2 virus, can be achieved through vaccination [1]. Vaccination programs have had a remarkable impact on the control of the COVID-19 burden with reports of greater than 90% reductions in mortality rate observed in vaccinated individuals of all ages and reductions in hospitalization by 71–87% [2], though it should be noted that the efficacies of different vaccines against variants of SARS-CoV-2 are variable [1].